FindTrial
Sign In

Ayahuasca, Esketamine and PTSD

Effects of Single Dose of Ayahuasca or Esketamine on Posttraumatic Stress Disorder: a Randomized, Double-blinded Study

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07317206
Enrollment
10
Registered
2026-01-05
Start date
2025-12-20
Completion date
2026-07-31
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Posttraumatic Stress Disorder (PTSD)

Brief summary

Double-blind, randomized trial comparing a single dose of oral ayahuasca or esketamine in patients with posttraumatic stress disorder.

Interventions

DRUGAyahuasca

oral ayahuasca

DRUGEsketamine

oral esketamine

Sponsors

University of Sao Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* posttraumatic stress disorder

Exclusion criteria

* psychiatric and other medical comorbidities

Design outcomes

Primary

MeasureTime frameDescription
Posttraumatic Stress Disorder Checklist for DSM-5From enrollment to the end of treatment at 3 weekshigher scores mean a worse outcome

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026